These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9365156)

  • 1. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.
    Mantzoros CS; Tzonou A; Signorello LB; Stampfer M; Trichopoulos D; Adami HO
    Br J Cancer; 1997; 76(9):1115-8. PubMed ID: 9365156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum steroids in relation to benign prostatic hyperplasia.
    Lagiou P; Mantzoros CS; Tzonou A; Signorello LB; Lipworth L; Trichopoulos D
    Oncology; 1997; 54(6):497-501. PubMed ID: 9394847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leptin in relation to prostate cancer and benign prostatic hyperplasia.
    Lagiou P; Signorello LB; Trichopoulos D; Tzonou A; Trichopoulou A; Mantzoros CS
    Int J Cancer; 1998 Mar; 76(1):25-8. PubMed ID: 9533757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
    Khosravi J; Diamandi A; Mistry J; Scorilas A
    J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex relationship between sex hormones, insulin resistance and leptin in men with and without prostatic disease.
    Grosman H; Fabre B; Lopez M; Scorticati C; Lopez Silva M; Mesch V; Mazza O; Berg G
    Aging Male; 2016; 19(1):40-5. PubMed ID: 26526283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
    Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between selected hormone and protein levels in serum and prostate tissue homogenates in men with benign prostatic hyperplasia and metabolic disorders.
    Grzesiak K; Rył A; Baranowska-Bosiacka I; Rotter I; Dołęgowska B; Słojewski M; Sipak-Szmigiel O; Ratajczak W; Lubkowska A; Metryka E; Piasecka M; Laszczyńska M
    Clin Interv Aging; 2018; 13():1375-1382. PubMed ID: 30122909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal predictors of prostate cancer: a meta-analysis.
    Shaneyfelt T; Husein R; Bubley G; Mantzoros CS
    J Clin Oncol; 2000 Feb; 18(4):847-53. PubMed ID: 10673527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer.
    Rannikko S; Adlercreutz H
    Prostate; 1983; 4(3):223-9. PubMed ID: 6189106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum steroids in relation to prostate cancer risk in a case-control study (Greece).
    Signorello LB; Tzonou A; Mantzoros CS; Lipworth L; Lagiou P; Hsieh C; Stampfer M; Trichopoulos D
    Cancer Causes Control; 1997 Jul; 8(4):632-6. PubMed ID: 9242480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Kristal AR; Schenk JM; Song Y; Arnold KB; Neuhouser ML; Goodman PJ; Lin DW; Stanczyk FZ; Thompson IM
    Am J Epidemiol; 2008 Dec; 168(12):1416-24. PubMed ID: 18945688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of relations between serum levels of epitestosterone, estradiol, testosterone, IGF-1 and prostatic specific antigen in men with benign prostatic hyperplasia and carcinoma of the prostate.
    Hill M; Bílek R; Safarík L; Stárka L
    Physiol Res; 2000; 49 Suppl 1():S113-8. PubMed ID: 10984080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of serum insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 in benign prostatic hyperplasia].
    Yu JP; Wu XM; Chen JG; Liu WM; Yang QX
    Zhonghua Nan Ke Xue; 2003 Aug; 9(5):341-3. PubMed ID: 14513639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of sex hormone levels and risk of prostate cancer.
    Gann PH; Hennekens CH; Ma J; Longcope C; Stampfer MJ
    J Natl Cancer Inst; 1996 Aug; 88(16):1118-26. PubMed ID: 8757191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
    Correa LL; Neto LV; Lima GA; Gabrich R; Miranda LC; Gadelha MR
    Int Braz J Urol; 2015; 41(1):110-5. PubMed ID: 25928516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone concentration, metabolic disorders and immunoexpression of androgen and estrogen-alpha receptors in men with benign prostatic hyperplasia and testosterone deficiency syndrome.
    Ryl A; Rotter I; Slojewski M; Dolegowska B; Grabowska M; Baranowska-Bosiacka I; Laszczynska M
    Folia Histochem Cytobiol; 2015; 53(3):227-35. PubMed ID: 26400665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer risk and serum levels of insulin and leptin: a population-based study.
    Hsing AW; Chua S; Gao YT; Gentzschein E; Chang L; Deng J; Stanczyk FZ
    J Natl Cancer Inst; 2001 May; 93(10):783-9. PubMed ID: 11353789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormones and hair patterning in men: a role for insulin-like growth factor 1?
    Signorello LB; Wuu J; Hsieh Cc; Tzonou A; Trichopoulos D; Mantzoros CS
    J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):200-3. PubMed ID: 10025745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.